VBI Vaccines Inc(VBIV)stock report

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).

Finance:
Market Cap:254.9M; Shares Outstanding:178.3M; Short Interest: 3.68%; Q3 2019(9/30/19): Cash 53.02M. Loss 16.16M

EPS and Sales:
https://finance.yahoo.com/quote/VBIV/financials?p=VBIV

Date EPS % last year % last quarter
2018.12.31 -0.9878 -62.33% -43.16%
2019.3.31 -0.15 21.38% 84.81%
2019.6.30 -0.2841 36.88% -89.40%
2019.9.30 -0.44 36.23% -54.88%

 

Date Sales % last year % last quarter
2018.12.31 3.36M 287.86% 401.49%
2019.3.31 0.36M 102.25% -89.29%
2019.6.30 1M 142.72% 177.78%
2019.9.30 1.65M 145.45% 65.00%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=VBIV&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/VBIV/institutional-ownership/

2020.01.10:
Total institutions: 76,no change
Shares hold: 73186.3k shares. no change
shares% hold: 41.06%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/VBIV/price-targe

Leave a Reply